四环医药(00460)发盈喜预计上半年净利润同比增长不低于217.2%

智通财经07-27

智通财经APP讯，四环医药(00460)发布公告，集团预期于截至2026年6月30日止六个月取得收入不低于人民币11.4亿元，与去年同期大致持平;取得期内净利润不低于人民币2.1亿元，较去年同期增长不低于217.2%。影响集团于该期间的财务业绩主要包括如下因素：1.医美业务保持稳健发展。集团医美板块持续受惠于核心产品乐提葆®(肉毒毒素)的稳定增长，以及再生类医美产品(包括童颜针及少女针)及功能性...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2654140099?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-27 12:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654140099","market":"hk","top_or_hot":-1,"title":"四环医药(00460)发盈喜 预计上半年净利润同比增长不低于217.2%","media":"智通财经","content":"<div>\n<p>智通财经APP讯，四环医药(00460)发布公告，集团预期于截至2026年6月30日止六个月取得收入不低于人民币11.4亿元，与去年同期大致持平;取得期内净利润不低于人民币2.1亿元，较去年同期增长不低于217.2%。影响集团于该期间的财务业绩主要包括如下因素：1.医美业务保持稳健发展。集团医美板块持续受惠于核心产品乐提葆®(肉毒毒素)的稳定增长，以及再生类医美产品(包括童颜针及少女针)及功能性...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1472466.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>四环医药(00460)发盈喜 预计上半年净利润同比增长不低于217.2%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n四环医药(00460)发盈喜 预计上半年净利润同比增长不低于217.2%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-27 12:08 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1472466.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，四环医药(00460)发布公告，集团预期于截至2026年6月30日止六个月取得收入不低于人民币11.4亿元，与去年同期大致持平;取得期内净利润不低于人民币2.1亿元，较去年同期增长不低于217.2%。影响集团于该期间的财务业绩主要包括如下因素：1.医美业务保持稳健发展。集团医美板块持续受惠于核心产品乐提葆®(肉毒毒素)的稳定增长，以及再生类医美产品(包括童颜针及少女针)及功能性...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1472466.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00460","symbol_name":"四环医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1472466.html","article_id":"2654140099","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654140099","pubTimestamp":1785125298,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，四环医药 发布公告，集团预期于截至2026年6月30日止六个月取得收入不低于人民币11.4亿元，与去年同期大致持平;取得期内净利润不低于人民币2.1亿元，较去年同期增长不低于217.2%。仿制药业务受国家集采等政策压力影响，集团持续推进仿制药业务优化及资产整合，相关资产剥离于该期间产生收益不低于人民币1.4亿元，进一步提升集团整体盈利水准及资源配置效率。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"00460":"四环医药"},"translate_title":"Sihuan Pharmaceutical (00460) issued a positive profit and expected its net profit in the first half of the year to increase by no less than 217.2% year-on-year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1.5},"content_text":"智通财经APP讯，四环医药(00460)发布公告，集团预期于截至2026年6月30日止六个月取得收入不低于人民币11.4亿元，与去年同期大致持平;取得期内净利润不低于人民币2.1亿元，较去年同期增长不低于217.2%。影响集团于该期间的财务业绩主要包括如下因素：1.医美业务保持稳健发展。集团医美板块持续受惠于核心产品乐提葆®(肉毒毒素)的稳定增长，以及再生类医美产品(包括童颜针及少女针)及功能性医美产品的持续放量，推动相关业务收入保持增长。医美业务于该期间取得收入不低于人民币6.8亿元，较去年同期增长不低于16.1%;分部业绩溢利不低于人民币3.2亿元，继续为集团重要的盈利来源。2.创新药业务商业化进程持续推进。多款已获批产品的商业化及国际化进展良好，合并营收迎来大幅增长，且实现大幅减亏。3.对外投资收益显著增加。主要是集团因合联营企业所投资项目成功IPO上市，于该期间确认投资收益不低于人民币1.1亿元。4.资产结构优化带来收益。仿制药业务受国家集采等政策压力影响，集团持续推进仿制药业务优化及资产整合，相关资产剥离于该期间产生收益不低于人民币1.4亿元，进一步提升集团整体盈利水准及资源配置效率。此外，随着集团医美及创新药两大核心板块相继进入收获期并保持高速增长，集团整体业绩结构持续优化，盈利能力稳步提升，标志着集团正式迈入高质量发展的新阶段。董事会认为，集团战略路径清晰、产品梯队完善、国际化进程加速，未来将继续坚持创新驱动与差异化布局，致力于为股东及投资者创造长期可持续的回报。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2654140099","isCrawlerRequest":true}

四环医药(00460)发盈喜 预计上半年净利润同比增长不低于217.2%

精彩评论

四环医药(00460)发盈喜预计上半年净利润同比增长不低于217.2%